PubMed Central (PMC) Search Page
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1996 | 2 |
| 2003 | 1 |
| 2004 | 3 |
| 2005 | 3 |
| 2006 | 9 |
| 2007 | 18 |
| 2008 | 63 |
| 2009 | 87 |
| 2010 | 58 |
| 2011 | 76 |
| 2012 | 60 |
| 2013 | 88 |
| 2014 | 89 |
| 2015 | 97 |
| 2016 | 102 |
| 2017 | 85 |
| 2018 | 97 |
| 2019 | 108 |
| 2020 | 233 |
| 2021 | 177 |
| 2022 | 180 |
| 2023 | 48 |
| 2024 | 133 |
| 2025 | 307 |
| 2026 | 296 |
-
Publication date
-
-
Publication stage
These filters represent the three primary types of content included in the PMC archive: 1) content published in a scholarly journal 2) peer-reviewed author manuscripts accepted for publication in a journal and 3) preprint versions of articles collected through the NIH Preprint Pilot, made public prior to peer review
-
-
Collections
The PMC Open Access Subset includes journal articles and preprints that are made available under license terms that allow reuse. Historical back issues refers to digitized content from print journals made available in PMC through the Biomedical Journal Digitization Projects.
-
"Br J Haematol"[Journal]
The embargo is the time during which the publisher retains exclusive rights to distribute articles. Those articles are made freely available on the PMC website after the embargo period has ended. Citations for articles under an embargo period will still display in the PMC results list by default. Choose “Exclude” to prevent embargoed articles from displaying in your results.
-
Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.
- Awan FT, Liu R, Huang HH, Bye M, Ahn KW, Krigsfeld G, Raz A, Wolfe H, Hamadani M.
- Br J Haematol. Author manuscript. 2026 Aug 31:10.1111/bjh.70803. doi: 10.1111/bjh.70803. Online ahead of print.
- PMCID: PMC13685468
Awan FT, et al.Br J Haematol. Author manuscript. 2026.PMCID: PMC13685468 -
Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity.
- Bleeke M, Simon A, Winkler B, Heine S, Eichinger A, von Both U, Siepermann M, El Amouri S, Borkhardt A, Pritschow Y, Novak W, Dworzak M, Goretzki S, Held C, Beutel K, Gams F, Rudolph H, Koscher L, Beusker PE, Hamelmann E, Weichert S, Häuser S, Mauritz M, Aydin M, Wiegering V, Grosse R, Misgeld R, Stiefel M, Töpfner N, Falke U, Imhof L, Tagliaferri L, Ebrahimi-Fakhari D, Groll A, Appel M, Naumann-Bartsch N, Nathrath M, Beck O, Heidtmann S, Tischer P, Schulze-Sturm U, Mücke U, Cario H.
- Br J Haematol. 2026 Sep 13;209(4):1845-1855. doi: 10.1111/bjh.70809.
- PMCID: PMC13674147
Bleeke M, et al.Br J Haematol. 2026.PMCID: PMC13674147 -
Functional assessment of inherited myeloid neoplasm-associated SAMD9L germline variants via Monoallelic CRISPR modelling.
- Vuelta E, Liquori A, Morín M, Soletto L, Marugal MÁ, Santiago-Balsera M, Gallardo M, Moreno-Pelayo MÁ, Cervera J, Sanjuan-Pla A.
- Br J Haematol. 2026 Aug 28;209(4):1538-1548. doi: 10.1111/bjh.70799.
- PMCID: PMC13674140
Vuelta E, et al.Br J Haematol. 2026.PMCID: PMC13674140 -
LTB-TREAT: A validated international prognostic model for time to treatment in low tumour burden follicular lymphoma.
- Barge L, Webb L, Pelecanos A, Waters N, Salvaris R, Lai S, Potezny T, Cashman H, Nguyen-Ngo C, Lee D, Yannakou CK, Hamad N, Chauchet A, Choquet S, Rossi C, Herbin A, Kanagaratnam L, Rodier C, Tam CS, Bhattacharyya A, Cheah CY, Hawkes EA, Morris K, Durot E, Tobin J, Hapgood G.
- Br J Haematol. 2026 Aug 27;209(4):1673-1683. doi: 10.1111/bjh.70748.
- PMCID: PMC13674130
Barge L, et al.Br J Haematol. 2026.PMCID: PMC13674130 -
The PRIME trial: An investigator-initiated, multicentre, phase II study of the poly(ADP-ribose) polymerase inhibitor olaparib in isocitrate dehydrogenase (IDH)-mutated relapsed/refractory acute myeloid leukaemia and myelodysplastic syndromes.
- Shallis RM, VanOudenhove J, Chandhok N, Watts J, Jeyakumar D, Reed DR, Bewersdorf JP, Durecki D, Boerner S, Little RF, Gore SD, Li J, Bao X, Chen L, Ghatak S, Prebet T, Bindra RS, Zeidan AM, Halene S.
- Br J Haematol. 2026 Aug 26;209(4):1891-1895. doi: 10.1111/bjh.70756.
- PMCID: PMC13674138
Shallis RM, et al.Br J Haematol. 2026.PMCID: PMC13674138 -
Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).
- Gallamini A, Viviani S, Rapezzi D, Patti C, Feugier P, Rambaldi A, Bijou F, Borra A, Borel C, Pace-Loscos T, Schiappa R, Chauvie S, Debaigt C, Guidetti A, Humbert O, De Colella JS.
- Br J Haematol. 2026 Aug 26;209(4):1619-1628. doi: 10.1111/bjh.70763.
- PMCID: PMC13674205
Gallamini A, et al.Br J Haematol. 2026.PMCID: PMC13674205 -
Clinical trials portfolio and regulatory outcomes of ixazomib in multiple myeloma: A systematic review and meta-analysis.
- Shah V, Shah D, Utzman P, Shah K, Swaminathan S, Mainou M, Chakraborty R, Goodman A, Al Hadidi S, Kelkar AH, Cliff ERS, Mohyuddin GR.
- Br J Haematol. 2026 Aug 23;209(4):1882-1885. doi: 10.1111/bjh.70757.
- PMCID: PMC13674204
Shah V, et al.Br J Haematol. 2026.PMCID: PMC13674204 -
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022.
- Comerford C, Hayden PJ, Eikema DJ, Koster L, Sauer S, Broers A, Rabin N, Bastie JN, Gedde-Dahl T, Giaccone L, Richardson D, Carlson K, Besemer B, de Colella JS, Zeiser R, Vincent L, Pabst T, Cairoli A, Schuermans C, Poiani M, Raj K, Drozd-Sokolowska J, Garderet L, Najjar IE, Beksac M, McLornan DP.
- Br J Haematol. 2026 Aug 19;209(4):1918-1922. doi: 10.1111/bjh.70759.
- PMCID: PMC13674124
Comerford C, et al.Br J Haematol. 2026.PMCID: PMC13674124 -
Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.
- Kislova M, Dmitrieva E, Naumova E, Pochtar M, Lugovskaya S, Kobzev Y, Loban A, Gladysheva M, Obukhova T, Biderman B, Sudarikov A, Volchkov E, Ivanova M, Ptushkin V, Visentin A, Nikitin E.
- Br J Haematol. 2026 Aug 19;209(4):1664-1672. doi: 10.1111/bjh.70761.
- PMCID: PMC13674212
Kislova M, et al.Br J Haematol. 2026.PMCID: PMC13674212 -
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
- Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F; German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL).
- Br J Haematol. 2026 Aug 18;209(4):1783-1796. doi: 10.1111/bjh.70735.
- PMCID: PMC13674134
Kunadt D, et al.Br J Haematol. 2026.PMCID: PMC13674134